<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03656562</url>
  </required_header>
  <id_info>
    <org_study_id>CVAY736X2208</org_study_id>
    <nct_id>NCT03656562</nct_id>
  </id_info>
  <brief_title>Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients</brief_title>
  <official_title>A Placebo-controlled, Patient and Investigator Blinded, Randomized Parallel Cohort Study to Assess Pharmacodynamics, Pharmacokinetics, Safety, Tolerability and Preliminary Clinical Efficacy of VAY736 and CFZ533 in Patients With Systemic Lupus Erythematosus (SLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety, tolerability, pharmacokinetics and therapeutic
      efficacy of treatment with either VAY736 or CFZ533 in patients with SLE to enable further
      development of these compounds as treatment in this disease population
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 13, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The investigational drug or placebo will be administered on top of SLE background therapy. Patients will be randomized at baseline into one of two treatment cohorts (VAY736 or CFZ533) and to either active or placebo double blind treatment within that cohort. From Week 29 onwards all patients will receive open label active treatment until week 53 in the respective cohort.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Patients, investigator staff, persons performing the assessments, and the clinical trial team (CTT) will remain blind to the identity of the treatment within each cohort from the time of randomization until end of the Week 29 visit</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>SRI-4 response status</measure>
    <time_frame>29 Weeks</time_frame>
    <description>SRI-4 response status at Week 29 (reduced steroid dose maintained between Weeks 17 and 29).
Clinical efficacy will be measured using the SLE Responder Index (SRI-4), a composite endpoint that incorporates SLEDAI-2K, BILAG 2004, and a visual analog scale (VAS) of physician-rated disease activity to determine patient improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PhGA VAS - overall disease activity</measure>
    <time_frame>from Baseline to Week 29</time_frame>
    <description>Changes between baseline and Week 29 in the Physicians' Global Assessment (PhGA) visual analog scale (VAS) assessing patient's overall disease activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGA VAS - global disease activity</measure>
    <time_frame>from baseline to Week 29</time_frame>
    <description>Changes between baseline and Week 29 in the Patient's Global Assessment (PGA) visual analog scale (VAS) assessing patient's global disease activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flare rate and time to first flare</measure>
    <time_frame>18 months</time_frame>
    <description>Flare rate and time to first flare, with flare defined as one new 'A' score or two or more 'B' score using BILAG -2004</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first flare</measure>
    <time_frame>18 months</time_frame>
    <description>Time to first flare, with flare defined as one new 'A' score or two or more 'B' score using BILAG -2004</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Cohort 1 - Cmax,ss</measure>
    <time_frame>18+ months</time_frame>
    <description>PK Cohort 1 (VAY736): free VAY736 serum concentration (Cmax at steady state)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Cohort 1 - Ctrough,ss</measure>
    <time_frame>18+ months</time_frame>
    <description>PK Cohort 1 (VAY736): free VAY736 serum concentration (Ctrough at steady state)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Cohort 2 - Cmax,ss</measure>
    <time_frame>18 months</time_frame>
    <description>PK Cohort 2 (CFZ533): free CFZ533 concentration in plasma (Cmax at steady state).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Cohort 2 - Ctrough,ss</measure>
    <time_frame>18 months</time_frame>
    <description>PK Cohort 2 (CFZ533): free CFZ533 concentration in plasma (Ctrough at steady state).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD Cohort 2 (CFZ533): total soluble CD40</measure>
    <time_frame>18 months</time_frame>
    <description>PD Cohort 2 (CFZ533): total soluble CD40 in plasma.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Systemic Lupus Erythematosus (SLE)</condition>
  <arm_group>
    <arm_group_label>Cohort 1 VAY736</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple doses of VAY736, s.c.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 VAY736 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>multiple doses of matching placebo s.c. until week 29. Multiple doses of VAY736, s.c from week 29 until week 53.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 CFZ533</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple doses of CFZ533, i.v.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 CFZ533 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>multiple doses of matching placebo i.v. until week 29. Multiple doses of CFZ533, i.v. from week 29 until week 53.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VAY736</intervention_name>
    <description>Powder for solution for injection</description>
    <arm_group_label>Cohort 1 VAY736</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VAY736 Placebo</intervention_name>
    <description>Solution for injection</description>
    <arm_group_label>Cohort 1 VAY736 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CFZ533</intervention_name>
    <description>Concentrate for solution for infusion</description>
    <arm_group_label>Cohort 2 CFZ533</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CFZ533 Placebo</intervention_name>
    <description>Solution for infusion</description>
    <arm_group_label>Cohort 2 CFZ533 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent must be obtained before any assessment is performed

          -  Fulfill ≥4 of the 11 American College of Rheumatology 1997 classification criteria for
             SLE

          -  Patient diagnosed with SLE for at least 6 months prior to screening

          -  Elevated serum titers at screening of ANA (≥1:80) of a pattern consistent with an SLE
             diagnosis, including at a minimum either anti-double stranded DNA (anti-ds DNA) or
             anti-Ro (SSA) or anti-La (SSB) or anti-nuclear ribonucleoprotein (anti-RNP) or
             anti-Smith (anti-Sm)

          -  Currently receiving corticosteroids and/or anti-malarial and/or thalidomide treatment
             and/or another DMARD on a stable dose according to protocol requirements

          -  SLEDAI-2K score of ≥6 at screening

          -  BILAG 2004 score of one &quot;A&quot; score either in the mucocutaneous or in the
             musculoskeletal domain or one &quot;B&quot; score in either the mucocutaneous or musculoskeletal
             domain and at least one &quot;A&quot; or &quot;B&quot; score in a second domain at screening

          -  Weigh at least 40 kg at screening

        Exclusion Criteria:

        Cohort 2 (CFZ533/Placebo) only:

          -  Patients who are at significant risk for thromboembolic events based on the following:

          -  History of either thrombosis or 3 or more spontaneous abortions

          -  Presence of lupus anticoagulant or significantly prolonged activated partial
             thromboplastin time (aPTT) consistent with co-existent anti-phospholipid syndrome and
             without concurrent prophylactic treatment with aspirin or anticoagulants as per local
             standard of care

        All Cohorts:

          -  History of receiving prior to screening:

          -  Within 12 weeks: i.v. corticosteroids, calcineurin inhibitors or other oral DMARD

          -  Within 24 weeks: cyclophosphamide or biologics such as intravenous Ig, plasmapheresis,
             anti-TNF-a mAb, CTLA4-Fc Ig (abatacept) or BAFF targeting agents (e.g., belimumab)

          -  Any B-cell depleting therapies (e.g., anti-CD20 mAb, anti-CD22 mAb, anti-CD52 mAb) or
             TACI-Ig (atacicept) administered within 52 weeks prior to screening, and a B-cell
             count &lt;50 cells/μ at the time of screening

          -  Evidence of past exposure to tuberculosis as assessed by Quantiferon testing at
             screening

          -  Presence of human immunodeficiency virus (HIV) infection at screening

          -  Severe organ dysfunction or life threatening disease; ECOG performance status &gt; 1 at
             screening

          -  Presence of WHO Class III-IV renal involvement with proliferative disease or nephrotic
             range proteinuria (above 2 g/day), corresponding to a urine protein creatinine ratio
             of approx. 200 mg/mmol or 1.77 g/g, currently requiring immune suppressive induction
             or maintenance treatment exceeding protocol-defined limits

          -  Active viral, bacterial or other infections at the time of screening or enrollment

          -  Receipt of live/attenuated vaccine within a 2-month period before first dosing

          -  Uncontrolled, co-existing serious disease, e.g., uncontrolled hypertension, heart
             failure, type I diabetes, thyroid disease within 3 months prior to first dosing, or
             significant, unresolved illness within 2 weeks prior to first dosing

          -  History of hypersensitivity to drugs of similar chemical class

          -  Chronic infection with hepatitis B (HBV) or hepatitis C (HCV). Subjects who are HBsAg
             negative and HBcAb positive are excluded unless negative for HBV DNA. Once past
             screening and enrolled into study, requirements for monitoring and antiviral treatment
             are enacted.

        Subjects with a positive HCV antibody test should have HCV RNA levels measured. Subjects
        with positive (detectable) HCV RNA should be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+81337978748</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ciudad Autonoma de Bs As</city>
        <zip>C1015ABO</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 2</city>
        <zip>128 50</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille</city>
        <zip>13003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris Cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pessac Cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>457 8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo ku</city>
        <state>Tokyo</state>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku ku</city>
        <state>Tokyo</state>
        <zip>162 8655</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160 8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suwon si</city>
        <state>Gyeonggi Do</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85 168</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-218</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>00-874</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>190068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona/ Cataluny/Espanya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>China</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 19, 2018</study_first_submitted>
  <study_first_submitted_qc>August 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2018</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systemic Lupus Erythematosus (SLE)</keyword>
  <keyword>Anti-CD40</keyword>
  <keyword>anti-BAFF-receptor</keyword>
  <keyword>B-cell depletion</keyword>
  <keyword>BAFF-receptor blockade</keyword>
  <keyword>ianalumab</keyword>
  <keyword>VAY736</keyword>
  <keyword>iscalimab</keyword>
  <keyword>CFZ533</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

